Almirall

Almirall, founded in 1943, is a prominent global biopharmaceutical company specializing in medical dermatology. Headquartered in Barcelona, Spain, the firm focuses on the research, development, manufacturing, and commercialization of prescription treatments for complex skin conditions, including psoriasis, atopic dermatitis, and actinic keratosis. By leveraging an advanced R&D pipeline and scientific innovation, Almirall addresses significant unmet needs within the dermatological space, maintaining a strong presence in both B2B and B2C markets.

The company operates with a workforce of 1,000-5,000 employees across 7 global locations. Almirall’s operational footprint supports a diverse portfolio of pharmaceutical products, ranging from medical devices to specialized therapeutic solutions. The organization integrates AI and genetic research into its innovation platform to accelerate drug discovery and patient care. With a commitment to scientific excellence, the company collaborates extensively with the global scientific community and academic institutions to advance dermatological medicine.

Almirall maintains a robust market position, evidenced by its consistent focus on high-value therapeutic areas and strategic alliances. Meet Almirall's team to learn about the leadership driving these initiatives and the organizational structure supporting their global operations. As a publicly traded entity under the ticker MSE: ALM, the company continues to expand its influence across Europe, North America, and other international markets. Through its dedicated focus on skin health and patient-centric innovation, Almirall remains a key player in the evolving biopharmaceutical landscape with annual revenue of $1.3B.